| 12/01/2025 15:30 |
Notice of Change to Scheduled Date to Commence Dividend Payments |
| 11/05/2025 16:00 |
Financial Briefing for the Second Quarter (Interim) of the Fiscal Year Ended March 31, 2026 (Fiscal 2025) |
| 11/04/2025 19:00 |
Notice Concerning Revisions to Financial Results Forecast |
| 11/04/2025 15:30 |
Supplementary Explanatory Materials on Financial Results for the Six Months Ended September 30, 2025 |
| 11/04/2025 15:30 |
Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP] |
| 10/23/2025 15:30 |
Linzagolix Approved for Marketing in Taiwan |
| 10/07/2025 15:30 |
Licensing Agreement for "Linzagolix" with Searchlight Pharma in Canada |
| 09/25/2025 15:30 |
Notice Regarding Sale of Investment Securities (Result) |
| 07/30/2025 17:00 |
Licensing Agreement with Viridian Therapeutics for "Veligrotug" and "VRDN-003" in Treatment of Thyroid Eye Disease |
| 07/29/2025 15:30 |
Consolidated Financial Results for the Three Months Ended June 30, 2025 [Japanese GAAP] |
| 07/29/2025 15:30 |
Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income |
| 07/29/2025 15:30 |
Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2025 |
| 07/24/2025 15:30 |
Notice Regarding Completion of Disposal of Treasury Stocks as Restricted Stock for Members of the Board and Corporate Officers |
| 07/01/2025 11:30 |
New Launch of TAVALISSE for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea |
| 06/24/2025 15:30 |
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers |
| 06/02/2025 08:00 |
Notice of Convocation Annual General Meeting 2025 |
| 05/08/2025 16:00 |
Financial Briefing for the Fiscal Year Ended March 31, 2025 (Fiscal 2024) |
| 05/08/2025 10:00 |
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System |
| 05/07/2025 16:30 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [Japanese GAAP] |
| 05/07/2025 16:30 |
Supplementary Explanatory Materials on Financial Results for the Fiscal Year Ended March 31, 2025 |
| 05/07/2025 16:30 |
Notice Concerning Dividends of Surplus (Increase in Dividend) |
| 05/07/2025 16:30 |
Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading |
| 05/07/2025 16:30 |
Notice Concerning Revision of the Executive Compensation System |
| 02/26/2025 15:30 |
Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan |
| 02/03/2025 15:30 |
Supplementary Explanatory Materials on Financial Results for the Nine Months Ended December 31, 2024 |
| 02/03/2025 15:30 |
Consolidated Financial Results for the Nine Months Ended December 31, 2024 [Japanese GAAP] |
| 01/21/2025 11:30 |
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea |
| 01/14/2025 11:30 |
Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations |
| 01/07/2025 15:30 |
Sub-licensing Agreement for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE with Tai Tien Pharmaceuticals in Taiwan |
| 12/23/2024 08:45 |
Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist YSELTY (generic name linzagolix). |
